Medtronic stock sits below an USD 103.92 consensus target

Published on 10/06/2026 at 16:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic stock delivered USD 9.76 billion in Q1 FY27 revenue on September 1, up 13.7 percent year over year. FY27 organic growth guidance rose to 7.25%-7.75%.

Editorialfoto eines Trading-Floors mit Händlern und Kursdiagrammen im Hintergrund — Medtronic plc (ISIN IE00BTN1Y115) Börsen-Editorial zeigt Trading-Floor der NYSE mit Kursdiagrammen im Hintergrund lebhaft, Illustration mit AI erstellt.

Medtronic plc (ISIN IE00BTN1Y115) was trading at USD 87.87 on the NYSE on October 6, 2026 at 10:58 a.m. ET, down 0.11 percent from the prior close. The company entered the new quarter with stronger fiscal 2027 guidance after its first-quarter revenue and adjusted earnings beat analyst expectations, as Yahoo Finance reported on September 1, 2026.

Revenue beat raised the outlook

In Q1 FY27, Medtronic generated USD 9.756 billion in revenue, up 13.7 percent from the prior-year quarter. Adjusted EPS reached USD 1.45 against a USD 1.39 consensus estimate, while GAAP diluted EPS was USD 1.14, according to Yahoo Finance.

The guidance change is the central operating signal. Medtronic lifted fiscal 2027 organic revenue growth guidance to 7.25%-7.75% from 6.75%-7.25% and increased adjusted EPS guidance to USD 5.94-6.00 from USD 5.90-6.00, Yahoo Finance reported on October 3, 2026.

Cardiac devices lead growth

The quarterly advance was broad across Medtronic's businesses. Cardiovascular revenue rose 19.5 percent, Diabetes increased 16.9 percent, Neuroscience grew 10.3 percent and Medical Surgical advanced 10.0 percent in Q1 FY27, according to Yahoo Finance.

The comparison carries a qualification because the quarter included an extra fiscal week. That calendar effect makes the 13.7 percent reported growth rate less useful as a direct guide to every later quarter, while the higher full-year outlook shows that management also sees underlying improvement, as Yahoo Finance explained on October 3, 2026.

Consensus target stays above the price

MarketBeat cited 28 analysts, including 19 Buy ratings and nine Hold ratings, for a Moderate Buy consensus and an average target of USD 103.92. That target stood 18.3 percent above the USD 87.87 NYSE price on October 6, 2026, based on the published consensus figures and the same-day quote.

MarketBeat also reported a USD 0.72 quarterly dividend scheduled for payment on October 16, 2026. The dividend adds an income component, but the valuation case still depends on whether cardiovascular growth and the upgraded fiscal outlook can offset the extra-week comparison and execution risks around the portfolio.

NYSE price and market value

Medtronic was last at USD 87.87 on the NYSE on October 6, 2026 at 10:58 a.m. ET, down 0.11 percent on the session. The market capitalization was USD 112.5 billion, and the 52-week range was USD 73.31 to USD 106.33.